Pfizer pairing progress in its GLP-1 obesity pipeline with confirmation of a US$0.43 second-quarter 2026 dividend signals a mix of growth ambition and income focus
doi: 10.3389/fimmu.2026.1744308 Received 11 November 2025 Revised 04 April 2026 Accepted 13 April 2026 Published 28 April 2026 Volume 17 - 2026 Edited by Francesco Caso, University of Naples Federico II, Italy Reviewed by Piero Ruscitti, University of LAquila, Italy Silvia Scriffignano, Fondazione Istituto G.Giglio, Italy Updates Copyright 2026 Ciancio, Maranini, Sandri, Amati, Bortoluzzi, Silvagni, Govoni and Giuggioli
Set realistic expectations: GLP-1 medications are valuable tools for weight management, but they are not quick fixes
Optimal results occur with consistent use over 3-6 months, as GHs effects are cumulative and require time for tissue remodeling